messenger RNA levels decrease in a subset of neurons of the
lateral striatum, cortex and hippocampus of transgenic Huntington's
disease mice. Neuroscience 98:705–713.
DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin
E, Vonsattel J-P, Carraway R, Reeves SA, Boyce FM, Aronin N
(1995) Huntingtin is a cytoplasmic protein associated with vesicles
in human and rat brain neurons. Neuron 14:1075–1081.
Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular
theory of depression. Arch Gen Psychiatry 54:597–604.
Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil
SM, Ge P, Vonsattel JP, Gusella JF, Joyner AL (1995) Inactivation
of the mouse Huntington's disease gene homolog Hdh. Science
269:407–410.
Franklin KBJ, Paxinos G (1997) The mouse brain atlas. Academic
Press.
Francis SH, Turko IV, Corbin JD (2000) Cyclic nucleotide
phosphodiesterases: relating structure and function. Prog Nucl Acid
Res Mol Biol 65:1–52.
Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura
K, Omori K (1999a) Cloning and characterization of a novel human
phosphodiesterase that hydrolyzes both cAMP and cGMP
(PDE10A). J Biol Chem 274:18438 –18445.
Fujishige K, Kotera J, Omori K (1999b) Striatum- and testis-specific
phosphodiesterase PDE10A: isolation and characterization of a rat
PDE10A. Eur J Biochem 266:1118 –1127.
Fujishige K, Kotera J, Yuasa K, Omori K (2000) The human phosphodiesterase PDE10A gene: genomic organization and evolutionary
relatedness with other PDEs containing GAF domains. Eur J Biochem 267:5943–5951.
Furuyama T, Iwashashi Y, Tano Y, Takagi H, Inahaki S (1994) Localization of 63 kDa calmodulin-stimulated phosphodiesterase mRNA
in the rat brain by in situ hybridization histochemistry. Mol Brain Res
26:331–336.
Giembycz MA (2001) Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary
disease. Exp Opin Invest Drugs 10:1361–1379.
Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF,
Wheeler VC, Persichetti F, MacDonald ME (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic
Huntington's disease knock-in mice. Hum Mol Gen 12:497–508.
Goldberg YP, Kalchman MA, Metzler M, Nasir J, Zeisler J, Graham R,
Koide HB, O'Kusky J, Sharp AH, Ross CA, Jirik F, Hayden MR
(1996) Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human
Huntington disease transcript. Hum Mol Gen 5:177–185.
Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in
Huntington's disease. Science 227:770 –773.
Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF,
Brundin P (2001) Resistance to NMDA toxicity correlates with
appearance of nuclear inclusions, behavioural deficits and changes
in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 14:1492–1504.
Harper PS (1992) The epidemiology of Huntington's disease. Hum
Gen 89:365–376.
Huntington's Disease Collaborative Research Group (1993) A novel
gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell 72:971–983.
Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, Sapp E, Wang
Y, Qin ZH, Chen JD, Nevins JR, Aronin N, DiFiglia M (2002)
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 277:7466 –7476.
Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K,
Takahashi H, Kondo R, Ishikawa A, Hayashi T, Saoito M, Tomoda
A, Miike T, Naito H, Ikuta F, Tsuji S (1994) Unstable expansion of
CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DR- PLA). Nat Genet 6:9 –13.
